Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9029988 | 0.87 | ALDH1A1 (0.43) | KDM4ECXCL8ALDH1A1LMNACYP1A2 | |
| SCHEMBL8830304 | 0.85 | GRIK1 (0.39) | KDM4ECXCL8ALDH1A1MEN1KMT2A | |
| Loviride SCHEMBL29457001 | 0.84 | ALOX15 (0.39) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Loviride SCHEMBL247781 | 0.84 | ALOX15 (0.39) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Loviride SCHEMBL29456999 | 0.84 | ALOX15 (0.39) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Loviride SCHEMBL247782 | 0.84 | ALOX15 (0.39) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| SCHEMBL9031893 | 0.84 | ELANE (0.41) | KDM4ECXCL8ALDH1A1LMNACYP1A2 | |
| SCHEMBL8830196 | 0.83 | CLCN2 (0.36) | CXCL8LMNAHPGDKMT2APKM | |
| SCHEMBL9031270 | 0.83 | SMN1; SMN2 (0.40) | KDM4ECXCL8ALDH1A1LMNACYP1A2 | |
| SCHEMBL14440013 | 0.81 | CXCL8 (0.43) | KDM4ECXCL8ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0538301-B1 | HIV-INHIBITING BENZENEACETAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1996-10-30 | — | — | EP | claimed |
| US-5556886-A | VIRICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-17 | — | — | US | claimed |
| CN-1107835-A | A process for preparing pharmaceutical composition showing properties in against human immunodeficiency virus | JANSSEN PHARMACEUTICA NV (BE) | 1995-09-06 | — | — | CN | claimed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | claimed |
| CN-1028990-C | Process for preparing phenylacetamide derivatives for inhibiting human immunodeficiency virus | JANSSEN PHARMACEUTICA NV (BE) | 1995-06-21 | — | — | CN | claimed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4342543-B1 | TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-1107835-A | A process for preparing pharmaceutical composition showing properties in against human immunodeficiency virus | JANSSEN PHARMACEUTICA NV (BE) | 1995-09-06 | — | — | CN | disclosed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| CN-1028990-C | Process for preparing phenylacetamide derivatives for inhibiting human immunodeficiency virus | JANSSEN PHARMACEUTICA NV (BE) | 1995-06-21 | — | — | CN | disclosed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0538301-A1 | HIV-INHIBITING BENZENEACETAMIDE DERIVATIVES. | JANSSEN PHARMACEUTICA NV (BE) | 1993-04-28 | — | — | EP | disclosed |
| CN-1058958-A | HIV inhibiting phenylacetamide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1992-02-26 | — | — | CN | disclosed |
| WO-1992000952-A1 | HIV-INHIBITING BENZENEACETAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | KDM4E 1603/4885CXCL8 4492/4885ALDH1A1 3454/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | KDM4E 2163/4885CXCL8 4410/4885ALDH1A1 3506/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | KDM4E 638/4885CXCL8 3702/4885ALDH1A1 3895/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | KDM4E 3080/4885CXCL8 4001/4885ALDH1A1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.